ABT - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 20, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Abbott faces substantial litigation risk related to infant formula, with over 1,700 lawsuits and significant jury awards, including a $495 million judgment.. Medical Devices segment sales grew 11.9% in 2025, driven by double-digit growth in key areas like Diabetes Care.

Top Concerns

  • !Gross margins improved due to efficiency initiatives, but higher costs and unfavorable foreign exchange present ongoing challenges.
  • !The Diagnostic Products segment continues to be impacted by the decline in COVID-19 testing sales and market challenges in China, affecting both revenue and margins.
  • !Ongoing tax disputes with the IRS involving significant proposed adjustments.
  • !Malaysia tax assessment of $413 million for property capital gains tax.
  • !Abbott faces substantial litigation risk related to infant formula, with over 1,700 lawsuits and significant jury awards, including a $495 million judgment.

Top Positives

  • +Revenue growth in 2025 was primarily driven by the Medical Devices and Established Pharmaceutical Products segments, with strong performance in areas like Diabetes Care and Structural Heart, though offset by declining COVID-19 testing sales.
  • +Operating cash flow shows a strong upward trend, benefiting from higher earnings and effective working capital management, supporting continued investment and shareholder returns.
  • +The company is strategically investing in SG&A to drive growth across its businesses, particularly in sales and marketing efforts.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is confidently optimistic with focus on favorable impact of margin improvement initiatives.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is high.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

3.0/10

Overall risk profile shows regulatory compliance and product approval risks as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

7.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

ABT 10-K Analysis: Abbott's $23B Bet on Its Lowest-Return Division

Analysis

JNJ 10-K Analysis: Three Clocks Running Down on the Dividend King

Analysis

MMM 10-K Analysis: Why 3M Reports Two Different Companies in One Filing